Global Antibody-oligonucleotide Conjugates (AOCs) Market Strategic Research Report

Scope of the Report

The global Antibody-oligonucleotide Conjugates (AOCs) market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.

AOCs (Antibody-Oligonucleotide Conjugates) consist of three main components: a carrier (antibody), a linker, and a small nucleic acid. They allow for targeted delivery, combining the antibody’s ability to bind to specific cells with the gene-silencing capability of small nucleic acids, addressing the delivery challenges faced by conventional small nucleic acid drugs.

The development of Antibody-Oligonucleotide Conjugates (AOCs) aims to address the inherent limitations of small nucleic acids, such as poor serum stability, low membrane permeability, and lack of tissue selectivity. AOCs combine the longer half-life and precise targeting capabilities of antibodies with the gene-silencing power of small nucleic acids, achieving high-precision selectivity and effective delivery to target cells.

The global Antibody-oligonucleotide Conjugates (AOCs) market is experiencing explosive growth, with the core driving force coming from clinical breakthroughs in rare diseases (such as Duchenne muscular dystrophy and myotonic dystrophy) and innovative needs for targeted tumor therapy. Leading companies Avidity Biosciences (AOC 1001 clinical phase II) and Dyne Therapeutics (FORCE™ platform) are leading the race. On the technical side, pH-sensitive linkers optimize oligonucleotide release and bispecific antibody design improves tissue penetration, but low lysosomal escape efficiency (<10%) and high large-scale production costs (single dose exceeds US$50,000) are still the main bottlenecks. Avidity has successfully concluded positive pre-BLA discussions with the FDA and has adjusted the BLA submission timeline to the first quarter of 2026, aiming to proceed via the U.S. Accelerated Approval pathway. AOC 1044 is expected to become the first commercialized AOC therapeutic. In the next 3-5 years, with more than 20 AOC pipelines entering the clinic (indications expanding to ophthalmology and CNS) and AI-driven conjugation design (such as generative AI-optimized antibody-oligonucleotide pairing) being implemented, this field is expected to replicate the successful path of ADC drugs and become the next tens of billions of dollars market for precision medicine.

This report presents a comprehensive overview of the global Antibody-oligonucleotide Conjugates (AOCs) market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Site-specific Coupling
• Random Coupling

Segment by Antibody Format

• Full-length IgG
• Fab
• scFv
• Nanbody/VHH
• Others

Segment by Application

• Rare and Genetic Diseases
• Cancer Treatment
• Central Nervous System Disorders

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Antibody-oligonucleotide Conjugates (AOCs) market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Rare and Genetic Diseases, Cancer Treatment, Central Nervous System Disorders evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact